MX2019005621A - Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. - Google Patents

Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.

Info

Publication number
MX2019005621A
MX2019005621A MX2019005621A MX2019005621A MX2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A MX 2019005621 A MX2019005621 A MX 2019005621A
Authority
MX
Mexico
Prior art keywords
arthritis
compositions
methods
treatment
cartilage damage
Prior art date
Application number
MX2019005621A
Other languages
English (en)
Spanish (es)
Inventor
Johnson Kristen
GOLDHAHN Jörg
Scotti Celeste
Vostiar Igor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019005621A publication Critical patent/MX2019005621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019005621A 2016-11-14 2017-11-13 Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. MX2019005621A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421534P 2016-11-14 2016-11-14
US201762560301P 2017-09-19 2017-09-19
PCT/IB2017/057081 WO2018087727A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Publications (1)

Publication Number Publication Date
MX2019005621A true MX2019005621A (es) 2019-08-12

Family

ID=60629753

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005621A MX2019005621A (es) 2016-11-14 2017-11-13 Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.
MX2022011897A MX2022011897A (es) 2016-11-14 2019-05-14 Composicion intraarticular para el tratamiento del cartilago y la artritis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011897A MX2022011897A (es) 2016-11-14 2019-05-14 Composicion intraarticular para el tratamiento del cartilago y la artritis.

Country Status (10)

Country Link
US (3) US11351223B2 (enExample)
EP (1) EP3538127A1 (enExample)
JP (2) JP2019535707A (enExample)
KR (2) KR20190084287A (enExample)
CN (2) CN109963579A (enExample)
AU (2) AU2017357785A1 (enExample)
CA (1) CA3043667A1 (enExample)
IL (1) IL266361B2 (enExample)
MX (2) MX2019005621A (enExample)
WO (1) WO2018087727A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
EP4430395A1 (en) * 2021-11-10 2024-09-18 Novartis AG Methods for determining the biological activity of angptl polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490483B1 (en) 2001-04-19 2015-06-03 The Scripps Research Institute In vivo incorporation of unnatural amino acids
DK1578949T3 (da) 2002-10-16 2009-07-27 Scripps Research Inst Stedspecifik optagelse af keto-aminnosyrer hos proteiner
KR20050073559A (ko) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
CN103289960B (zh) 2003-04-17 2017-04-26 斯克利普斯研究院 扩展真核生物遗传密码
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
DE602004011789T2 (de) 2003-07-07 2009-02-12 The Scripps Research Institute, La Jolla Zusammensetzungen der orthogonalen Lysyl-tRNA und Aminoacyl-tRNA Synthetase Paaren und ihre Verwendungen
EP1794323B1 (en) 2004-09-21 2014-08-06 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
AU2005330514B2 (en) 2004-10-27 2011-05-12 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
CA2638763A1 (en) 2006-03-09 2007-09-13 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
CN102307902B (zh) * 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014151953A1 (en) * 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
UY36118A (es) * 2014-05-13 2016-01-08 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Also Published As

Publication number Publication date
RU2019117884A (ru) 2020-12-14
EP3538127A1 (en) 2019-09-18
US11351223B2 (en) 2022-06-07
CA3043667A1 (en) 2018-05-17
KR20190084287A (ko) 2019-07-16
US20190269754A1 (en) 2019-09-05
IL266361A (en) 2019-06-30
KR20240045351A (ko) 2024-04-05
MX2022011897A (es) 2022-10-18
IL266361B1 (en) 2023-10-01
AU2017357785A1 (en) 2019-04-11
CN109963579A (zh) 2019-07-02
US20250302915A1 (en) 2025-10-02
AU2020281098A1 (en) 2021-01-14
WO2018087727A1 (en) 2018-05-17
US20220331398A1 (en) 2022-10-20
AU2020281098B2 (en) 2024-05-02
JP2019535707A (ja) 2019-12-12
RU2019117884A3 (enExample) 2021-02-05
AU2017357785A2 (en) 2019-05-02
CN117860868A (zh) 2024-04-12
IL266361B2 (en) 2024-02-01
JP2023039962A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
UY37018A (es) Inhibidores bicíclicos de pad4
CR20150466A (es) Péptidos y composiciones para el tratamiento de daño articular
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CO2019014647A2 (es) Composiciones inmunogénicas
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
UY36286A (es) Tratamientos médicos basados en anamorelina